Scientific work

Prof. Dr. Siren Sezer

537 publications. The source of the information is stated next to each publication.

Back to profile

  1. Akçay A, Ozdemir FN, Ataç FB, Sezer S, Verdi H, Arat Z, Haberal M.

    Source: medicana.com.tr profile page

  2. Transplant Proc. 2004 Jan-Feb;36(1):35-7.

    Source: medicana.com.tr profile page

  3. 164Panel reactive antibody positivity and associated HLA antibodies in Turkish renal transplant candidates.

    Source: medicana.com.tr profile page

  4. Ozdemir FN, Sezer S, Akcay A, Arat Z, Turan M, Gulmus S, Kulah E, Haberal M.Transpl Immunol. 2004 Jan;12(2):185-8.PMID:14967317

    Source: medicana.com.tr profile page

  5. 165Predictors of hematopoietic response after renal transplantation.

    Source: medicana.com.tr profile page

  6. Arat Z, Sezer S, Ozdemir FN, Uyar M, Turan M, Haberal M.

    Source: medicana.com.tr profile page

  7. Transplant Proc. 2003 Nov;35(7):2716-7..PMID:14612088

    Source: medicana.com.tr profile page

  8. 166HCV antibody positivity significantly affects renal allograft survival.

    Source: medicana.com.tr profile page

  9. Ozdemir FN, Micozkadioglu H, Sezer S, Arat Z, Gürsoy M, Boyacioglu S, Haberal M.Transplant Proc. 2003 Nov;35(7):2701-2.. PMID: 14612081

    Source: medicana.com.tr profile page

  10. 167Contribution of late acute rejection to long-term renal allograft survival in patients with chronic allograft nephropathy.

    Source: medicana.com.tr profile page

  11. Sezer S, Ozdemir FN, Akcay A, Colak T, Kut A, Haberal M.

    Source: medicana.com.tr profile page

  12. Transplant Proc. 2003 Nov;35(7):2637-8..PMID: 14612049

    Source: medicana.com.tr profile page

  13. 168Assessment of risk factors for chronic allograft nephropathy in renal transplant patients.

    Source: medicana.com.tr profile page

  14. Sezer S, Ozdemir FN, Agca E, Colak T, Arat Z, Haberal M.

    Source: medicana.com.tr profile page

  15. Transplant Proc. 2003 Nov;35(7):2634-6..PMID:14612048

    Source: medicana.com.tr profile page

  16. 169Do serum albumin and aminotransferase levels predict renal graft outcome: a 5-year follow-up.

    Source: medicana.com.tr profile page

  17. Sezer S, Ozdemir FN, Külah E, Colak T, Turan M, Haberal M.

    Source: medicana.com.tr profile page

  18. Transplant Proc. 2003 Nov;35(7):2607-8. PMID:14612037

    Source: medicana.com.tr profile page

  19. 170Influence of recipient family history of atherosclerosis of renal allograft outcome.

    Source: medicana.com.tr profile page

  20. Ozdemir FN, Cantürk F, Colak T, Sezer S, Agca E, Haberal M.

    Source: medicana.com.tr profile page

  21. Transplant Proc. 2003 Nov;35(7):2602-4. PMID:14612035

    Source: medicana.com.tr profile page

  22. 171 Triad of malnutrition, inflammation, and atherosclerosis in hemodialysis patients.Sezer S, Ozdemir FN, Arat Z, Turan M, Haberal M.

    Source: medicana.com.tr profile page

  23. Nephron. 2002 Jul;91(3):456-62.PMID:12119477

    Source: medicana.com.tr profile page

  24. 172Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients.

    Source: medicana.com.tr profile page

  25. Sezer S, Ozdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M.

    Source: medicana.com.tr profile page

  26. Artif Organs. 2002 Apr;26(4):366-70.PMID:11952508

    Source: medicana.com.tr profile page

  27. 173The association of interdialytic weight gain with nutritional parameters and mortality risk in hemodialysis patients.

    Source: medicana.com.tr profile page

  28. Sezer S, Ozdemir FN, Arat Z, Perim O, Turan M, Haberal M.

    Source: medicana.com.tr profile page

  29. Ren Fail. 2002 Jan;24(1):37-48.PMID:11921697

    Source: medicana.com.tr profile page

  30. 174The association of interdialytic weight gain with nutritional parameters and mortality risk in hemodialysis patients.

    Source: medicana.com.tr profile page

  31. 174Spectrum of liver damage and correlation with clinical and laboratory parameters in HCV infected hemodialysis patients.

    Source: medicana.com.tr profile page

  32. Sezer S, Ozdemir BH, Arat Z, Turan M, Ozdemir NF, Haberal M.

    Source: medicana.com.tr profile page

  33. Ren Fail. 2001 Nov;23(6):807-18.PMID:11777320

    Source: medicana.com.tr profile page

  34. 175Predictors of serum albumin level in patients receiving continuous ambulatory peritoneal dialysis.

    Source: medicana.com.tr profile page

  35. Sezer S, Ozdemir FN, Akman B, Arat Z, Anaforoglu I, Haberal M.

    Source: medicana.com.tr profile page

  36. Adv Perit Dial. 2001;17:210-4.PMID:11510278

    Source: medicana.com.tr profile page

  37. 176The effect of simvastatin on panel-reactive antibody and crossmatch positivity.

    Source: medicana.com.tr profile page

  38. Ozdemir FN, Sezer S, Turan M, Colak T, Arat Z, Gülmüş S, Haberal M.

    Source: medicana.com.tr profile page

  39. Transplant Proc. 2001 Aug;33(5):2842-3. No abstract available.

    Source: medicana.com.tr profile page

  40. 177Ferritin levels can be a good predictor for HCV viremia in potential renal transplant candidates. Sezer S, Ozdemir FN, Güz G, Ozdemir BH, Sengül S, Arat Z, Turan M, Demirhan B, Haberal M.

    Source: medicana.com.tr profile page

  41. Transplant Proc. 2001 Aug;33(5):2796-8. No abstract available.

    Source: medicana.com.tr profile page

  42. 178Atherosclerosis risk is higher in continuous ambulatory peritoneal dialysis patients than in hemodialysis patients.

    Source: medicana.com.tr profile page

  43. Ozdemir FN, Güz G, Sezer S, Arat Z, Turan M, Haberal M.Artif Organs. 2001 Jun;25(6):448-52 PMID:11453874

    Source: medicana.com.tr profile page

  44. 179Is hepatitis C virus infection a risk factor for panel-reactive antibody positivity?

    Source: medicana.com.tr profile page

  45. Ozdemir FN, Sezer S, Güz G, Arat Z, Turan M, Haberal M.

    Source: medicana.com.tr profile page

  46. Transpl Int. 2000;13 Suppl 1:S31-3.PMID:11111957

    Source: medicana.com.tr profile page

  47. 180What happens after conversion of treatment to continuous ambulatory peritoneal dialysis from hemodialysis?

    Source: medicana.com.tr profile page

  48. Sezer S, Ozdemir N, Arat Z, Güz G, Sengül S, Akman B, Haberal A, Turan M, Haberal M.Adv Perit Dial. 2000;16:177-81. PMID: 11045288

    Source: medicana.com.tr profile page

  49. 181High frequency of amyloid lymphadenopathy in uremic patients.

    Source: medicana.com.tr profile page

  50. Güz G, Ozdemir BH, Sezer S, Yakupoglu U, Demirhan B, Ozdemir FN, Haberal M.Ren Fail. 2000;22(5):613-21. PMID: 11041293

    Source: medicana.com.tr profile page